Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648167 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
A Phase 2 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00648167 is a Phase 2 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT00648167, a Phase 2 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
Interventions
- DRUG ferric citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648167
The ClinicalTrials.gov registry entry for NCT00648167 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ferric citrate is the first listed.
NCT00648167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648167 about?
NCT00648167 is a clinical study titled "A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)". This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
What is the current status of trial NCT00648167?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2008-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00648167?
The interventions under investigation include: ferric citrate (DRUG).
Who is sponsoring clinical trial NCT00648167?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.